June 30, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD), will present new data and technology for its AI-enabled Plaque Analysis at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting, including final primary endpoint data from the DECIDE Registry. The SCCT Annual Scientific Meeting is taking place July 17-20, 2025 in Montreal.
In the DECIDE Registry, Heartflow’s AI-enabled Plaque Analysis led to medical management change in over half of patients beyond coronary computed tomography angiography (CCTA) alone. Full insights on medical management and clinical outcomes will be presented at the SCCT meeting.
DECIDE Registry investigator Cian McCarthy, MB, BCH, BAO, SM, is the first-place recipient of the 2025 SCCT Clinical Trials and Registries Award. The award recognizes clinical trials that use CCTA-based analyses to detect atherosclerotic burden in the diagnosis and treatment of CAD, as well as demonstrate a positive impact on patient outcomes. SCCT will present Dr. McCarthy with the award at the opening session of SCCT 2025 on July 18, followed by a presentation of the study results.
The DECIDE Registry is the largest prospective study of its kind, collecting real-world data from multiple sites investigating how HeartFlow’s AI-enabled Plaque Analysis informs medical management plans compared to CCTA alone for patients with suspected CAD. Approximately 20,000 patients will be enrolled at over 30 sites across the United States.
Heartflow will also showcase its next generation Plaque Analysis technology and a vastly expanded data set of age- and sex-specific nomograms for atherosclerotic plaque. Heartflow’s numerous presentations at SCCT, demonstration of new Plaque Analysis technology, and recognition of the DECIDE study by the SCCT scientific community all underscore Heartflow’s investment in clinical evidence and technology with continued unwavering commitment to being at the forefront of cardiovascular management.
“As Heartflow marks 15 years of innovation and SCCT celebrates its 20th annual meeting, we’re proud to lead the way in transforming how CAD is diagnosed, treated and managed,” said Campbell Rogers, M.D., FACC, Chief Medical Officer of Heartflow. “This year, we’re especially excited to share our next generation AI-enabled Plaque Analysis technology and our award-winning clinical research. With the DECIDE Registry and enhanced technology, we’re equipping clinicians with deeper insights that lead to real-world impact, guiding more confident, personalized and precise treatment decisions for patients.”
Heartflow’s data presentations at SCCT will include:
- DECIDE Registry Primary Endpoint: Guiding Implementation of Preventative Care Strategies for Patients with Atherosclerotic Plaque on Coronary Computed Tomographic Angiography: Primary Outcomes of the DECIDE (Artificial Intelligence-Derived Plaque Quantification: CTA and AI-CPA for Determining Effective CAD Management) Registry. It will be presented by Cian McCarthy, MB, BCH, BAO, SM.
- DECIDE Registry Primary Endpoint: Guiding Preventive Care Strategies for Patients with Atherosclerotic Plaque on Coronary Computed Tomographic Angiography: Primary Outcomes of the DECIDE (Artificial Intelligence-Derived Plaque Quantification: CTA and AI-CPA for Determining Effective CAD Management) Registry. The presenter will be Sarah Rinehart, M.D., FACC
- Expanded Plaque Nomogram: CT-Derived Nomograms of Coronary Plaque Volume by Age and Sex, presented by Georgios Tzimas, M.D.
- Cost Economics: Modeling Long-term Outcomes and Costs of Care Guided By AI-enabled CCTA Plaque Analysis as Compared to Standard of Care in Patients Undergoing CCTA for Stable Chest Pain. Suzanne J. Baron, M.D., will be the presenter.
See the full schedule at heartflow.com/SCCT.
For more information on Heartflow's cardiovascular care at www.heartflow.com.
July 23, 2024 
